Delek US Holdings: The Stock Is No Longer the Bargain It Was

Delek US Holdings reported a strong first quarter, beating earnings expectations. The stock is now up 123% year-to-date, sitting near $66.

The underlying business has turned a corner. Adjusted EBITDA - earnings before interest, taxes, depreciation, and amortization, a rough proxy for cash earnings - in Q1 2026 was $211.7 million, a massive improvement from the $33.6 million reported a year earlier. Refining segment adjusted EBITDA swung from a $27 million loss to a $155.3 million profit, driven by crack spreads (the difference between crude oil input costs and refined product output prices) that were 63.8% higher on average. The logistics segment - a more predictable, fee-like cash flow stream through Delek Logistics Partners - generated $132.4 million, up from $123.2 million a year prior.

Now let's talk about the cash flow profile, which is where the story actually lives. On a trailing twelve-month basis, Delek US generated $1.059 billion in operating cash flow. After $595 million in capital expenditures, free cash flow came to $464 million - a 156% year-over-year increase. That is the number that has changed investor minds. The company's Enterprise Optimization Plan, which management has now increased to approximately $220 million in annual run-rate cash flow improvements, is delivering. The restructuring of inventory intermediation agreements added another $40 million in incremental free cash flow. The Big Spring refinery turnaround was completed safely, on time, and on budget, restoring full system reliability going into peak driving season.

From a valuation perspective, the question has shifted from "is the business improving?" to "has the stock already done the work?" Delek US now trades at 12.2 times EV/EBITDA (enterprise value divided by EBITDA, a multiple that compares the total value of the business to its cash earnings), compared to 14.9 times for Marathon Petroleum and 13.0 times for Phillips 66. There is still a discount to those faster-growing, better-capitalized peers - but not one that screams bargain. At a $4.06 billion market cap and $6.62 billion enterprise value, the stock has moved from deeply undervalued to reasonably priced. If you argue that Delek should trade at peer-average multiples, the upside from here is single digits, not the 50-to-100% that made this a Strong Buy at $20.

The balance sheet remains heavy. Consolidated total debt stands at $7.27 billion against $624 million in cash, for net debt of $2.56 billion. Total equity is a thin $302 million, producing a debt-to-equity ratio of over 1000% - an accounting artifact of the parent-subsidiary structure, but one that matters for covenant and refinancing risk. It is worth noting that a large portion of that consolidated debt sits within Delek Logistics Partners. On a standalone basis, Delek US carries $889 million in debt and a $274 million net debt position, which is manageable. The company recently refinanced its revolving credit facilities, increasing consolidated borrowing capacity by $300 million and extending maturities to 2031. That provides breathing room, but leverage is still elevated.

The logistics segment deserves its own attention. Delek Logistics Partners gave 2026 adjusted EBITDA guidance of $520 to $560 million - the kind of fee-based, throughput-driven cash flow that normally commands a valuation premium. DKL has successfully advanced its Delaware Basin operations, completed its first acid gas injection well, and grown third-party cash flows. The economic separation between DK and DKL continues to widen, which should eventually improve valuation visibility for both entities. But DKL's stable earnings power has not yet translated into a midstream-style multiple for the combined business, and the parent-level debt structure continues to suppress the sum-of-the-parts argument.

The dividend is safe. The quarterly payout of $0.255 per share works out to $1.02 annually, yielding 1.9% at current prices. Free cash flow of $464 million TTM easily covers the $15.6 million paid per quarter, and the payout ratio - while showing as a negative on a GAAP earnings basis - is more than covered on a cash basis. That is not a concern.

Now let's address the risk scenario, because that is what has changed the most for this stock. The primary risk is normalization of refining margins. Crack spreads that are 63.8% above prior-year levels do not stay elevated indefinitely. Small refinery exemptions granted earlier in 2025 provided roughly $356 million in year-to-date cost-of-materials relief, but those benefits are temporary by nature. If crack spreads compress back toward historical averages and SRE relief unwinds, Delek's EBITDA could retreat toward the $300-to-$400 million annual range - still positive, but enough to justify the current price rather than imply further upside. Even if margins normalize, the Enterprise Optimization Plan's structural cost improvements should provide a floor. But they won't carry the stock higher from here without another round of margin expansion.

While it's true that Delek US still trades below its largest refining peers on an EV/EBITDA basis, I would argue that the margin-of-safety cushion that made this stock so attractive has largely evaporated. A 123% year-to-date return means the market has already absorbed most of the cash flow recovery story. The next catalyst - whether it's a sum-of-the-parts unlock via DKL separation, further EOP execution, or sustained margin strength - would need to surprise to the upside to justify additional gains.

The earnings beat was real. The cash flow turnaround is real. But the stock is no longer the bargain it was six months ago. All things considered, the operating improvement is encouraging, but the risk/reward has deteriorated from the level that justified an aggressive rating. I am downgrading Delek US Holdings from Strong Buy to Hold.